It is well established that Paxil carries a risk of suicide in children and teens. Nonetheless, GlaxoSmithKline has been conducting a study of the antidepressant using children as young as seven.
The drug carries a “black box” stating that it is twice as likely to generate lethal thoughts as a placebo.
“The primary aim of the study is not to find out why Paxil makes some children kill themselves. Rather, it’s yet another efficacy study, which the drug doesn’t need because it was approved years ago ...
If the results suggest a lower suicide risk, expect GSK to play them up. If they’re bad, expect the company to dismiss them in favor of the primary endpoint results.”